摘要
目的探讨新辅助内分泌治疗联合化疗对前列腺癌患者预后的影响。方法依据治疗方式的不同将120例前列腺癌患者分为手术组和联合组,每组60例,手术组患者给予前列腺癌根治术治疗,联合组患者在前列腺癌根治术前给予新辅助内分泌治疗联合化疗。比较两组患者血清前列腺特异性抗原(PSA)、血管内皮生长因子(VEGF)、T淋巴细胞亚群(CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+))、生活质量[欧洲癌症研究与治疗组织生命质量测定量表(EORTC QLQ-C30)]及无生化复发生存情况。结果治疗后,两组患者血清PSA、VEGF水平均低于本组治疗前,CD3^(+)、CD4^(+)水平和CD4^(+)/CD8^(+)均高于本组治疗前,且联合组患者血清PSA、VEGF水平均低于手术组,CD3^(+)、CD4^(+)水平和CD4^(+)/CD8^(+)均高于手术组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者EORTC QLQ-C30量表各维度评分均高于本组治疗前,且联合组患者EORTC QLQ-C30量表各维度评分均高于手术组,差异均有统计学意义(P﹤0.05)。术后6、12个月,手术组患者的无生化复发生存率分别为48.33%、25.00%,分别低于联合组患者的86.67%、66.67%,差异均有统计学意义(P﹤0.05)。结论新辅助内分泌治疗联合化疗可有效提高前列腺癌患者的生活质量,改善免疫功能,提高无生化复发生存率。
Objective To investigate the effect of neoadjuvant endocrine therapy combined with chemotherapy on the prognosis of patients with prostate cancer.Method A total of 120 prostate cancer patients were divided into surgery group and combined group according to different treatment methods,with 60 cases in each group.Patients in the surgery group were given radical prostatectomy,and patients in the combined group were given neoadjuvant endocrine therapy combined with chemotherapy before radical prostatectomy.Serum prostate-specific antigen(PSA),vascular endothelial growth factor(VEGF),T lymphocyte cell subsets(CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)),quality of life[European Organization for Research and Treatment of Cancer quality of life questionnaire core 30(EORTC QLQ-C30)]and relapse-free survival were compared between the two groups.Result After the treatment,the serum PSA and VEGF levels of both groups were lower than those before the treatment,and the CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)were higher than those before the treatment,the serum PSA and VEGF levels in the combined group were lower than those in the surgery group,and the CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)were higher than those in the surgery group,and the differences were statistically significant(P<0.05).After the treatment,the scores of all dimensions of the EORTC QLQ-C30 scale in the two groups were higher than those before the treatment,and the scores in the combined group were higher than those in the surgery group,and the differences were statistically significant(P<0.05).Six and twelve months after the surgery,the rate of relapse-free survival in the surgery group were 48.33%and 25.00%,which were lower than 86.67%and 66.67%in the combined group,and the differences were statistically significant(P<0.05).Conclusion Neoadjuvant endocrine therapy combined with chemotherapy could effectively improve prostate cancer patients’quality of life,improve their immune function and relapsefree survival rate.
作者
董山峰
宋瑞彬
胡耀宇
郑保良
DONG Shanfeng;SONG Ruibin;HU Yaoyu;ZHENG Baoliang(Department of Urology Surgery,Central Hospital of Jiaozuo Coal Industry(Group)Co.,Ltd.,Jiaozuo 454000,He’nan,China)
出处
《癌症进展》
2023年第5期574-577,共4页
Oncology Progress
关键词
前列腺癌
新辅助内分泌治疗
化疗
生活质量
预后
prostate cancer
neoadjuvant endocrine therapy
chemotherapy
quality of life
prognosis
